Zusammenfassung
Neuroendokrine Tumoren (NET) werden klinisch in funktionelle und nichtfunktionelle Tumoren unterschieden. Hochdifferenzierte Tumoren stellen die überwiegende Mehrzahl der NET (90 %) dar. Diese zeichnen sich durch einen hohen Besatz an Somatostatinrezeptorsubtypen aus und sind entsprechend mit der Somatostatinrezeptorszintigraphie (Octreoscan) und der PET/CT darstellbar. Letztere ist in Bezug auf eine höhere Sensitivität und der häufigeren Detektion von Metastasen der Szintigraphie überlegen. Bei funktionellen pankreatischen Tumoren ist die PET/CT-Diagnostik (mit 68Ga-DOTATOC oder 18F-DOPA) oft therapieentscheidend, da für eine kurative Resektion die exakte Lokalisation essenziell ist. Nichtkurativ resektable NET werden mittels antisekretorischer und antiproliferativer Ansätze therapiert. Je nach Vorkommen und Stadium werden auch die Somatostatinrezeptor-vermittelte Radiorezeptortherapie (PPPR) und lokoregionale Verfahren angewandt. Bei Auswahl der PRRT leistet die PET/CT einen wertvollen Beitrag.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97: 934–959
Yao JC, Hassan M et al. (2008) One hundred years after »carcinoid «: Epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 26(18): 3063–3072
Rindi G, Kloppel G, Ahlmann H et al. (2006) TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 449(4): 395–401
Modlin IM, Gustafsson BI, Moss SF, Pavel M et al. (2010) Chromogranin A: Biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 17: 2427–2443
Gabriel M, Decristoforo C, Kendler D et al. (2007) 68 Ga-DOTATyr3- octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: 508–18
Kann PH, Balakina E, Ivan D et al. (2006) Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: An endoscopic ultrasound imaging study. Endocr Relat Cancer 13(4): 1195–1202
Sundin A, Vullierme MP, Kaltsas G et al. (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 90(2): 167–183
Eriksson B, Kloppel G, Krenning E et al. (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87(1): 8–19
Modlin M, Pavel M, Kidd M, Gustadsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31(2): 169–188
Steinmuller T, Kianmanesh R, Falconi M et al. (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1): 47–62
Kwekkeboom DJ, de Herder WW, van Eijck CHJ, Kam BL, van Essen M, Teunissen JJM, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40(2): 78–88
Halfdanarson TR et al. (2008) Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 19(10): 1727–1733
Zhuge Y et al. (2009) Pediatric intestinal foregut and small bowel solid tumors: A review of 105 cases. J Surg Res 156(1): 95–102
Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36(3): 228–247
Machens A. et al. (2007) Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): A multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 67(4): 613–622
Marini F et al. (2006) Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 1: 38
Pieterman CR et al. (2009) Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 70(4): 575–581
Tessonnier L, Sebag F, Ghander C et al. (2010) Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 95(1): 303–307
Kapoor RR et al. (2009) Hyperinsulinaemic hypoglycaemia. Arch Dis Child 94(6): 450–457
Hussain K et al. (2007) Hyperinsulinaemic hypoglycaemia: Biochemical basis and the importance of maintaining normoglycaemia during management. Arch Dis Child 92(7): 568–570
Hussain K (2007) Insights in congenital hyperinsulinism. Endocr Dev 11: 106–121
Pieterman CR et al. (2009) Multiple endocrine neoplasia type 1 (MEN1): Its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 70(4): 575–581
Kuijpers SC, Noordam C, Boelen C, Wijnen R (2004) Congenital hyperinsulinism in 15 infants, 1981–1999; experiences and new insights. Ned Tijdschr Geneeskd 148(3): 140–143
Meissner T et al. (2003) Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 149(1): 43–51
Kapoor RR, James C, Hussain K (2009) Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. Nat Clin Pract Endocrinol Metab 5(2): 101–112
James C et al. (2009) The genetic basis of congenital hyperinsulinism. J Med Genet 46(5): 289–299
De Leon DD, Stanley CA (2007) Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab 3(1): 57–68
Giurgea I et al. (2006) The Knudson’s two-hit model and timing of somatic mutation may account for the phenotypic diversity of focal congenital hyperinsulinism. J Clin Endocrinol Metab 91(10): 4118–4123
Suchi M, MacMullen CM, Thornton PS et al. (2006) Molecular and immunohistochemical analyses of the focal form of congenital hyperinsulinism. Mod Pathol 19(1): 122–129
Sempoux C et al. (2004) Focal and diffuse forms of congenital hyperinsulinism: The keys for differential diagnosis. Endocr Pathol 15(3): 241–246
Capito C et al. (2009) Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 253(1): 216–222
Mohnike K et al. (2008) [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res 70(2): 65–72
Barthlen W et al. (2008) Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab 93(3): 869–875
Kapoor RR, Gilbert C, Mohnike K, Blankenstein O et al. (2008) Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas. Arch Dis Child Fetal Neonatal Ed 93(2): F166
Ribeiro MJ, Boddaert N et al. (2007) The added value of [18F] fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: A retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 34(12): 2120–2128
Ribeiro MJ, Boddaert N et al. (2007) Functional imaging of the pancreas: The role of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Endocr Dev 12: 55–66
Mohnike K, Blankenstein O et al. (2006) Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 66(1): 40–42
Otonkoski T et al. (2006) Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 55(1): 13–18
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Blankenstein, O., Pavel, M. (2016). Neuroendokrine Tumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-662-48842-3_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48841-6
Online ISBN: 978-3-662-48842-3
eBook Packages: Medicine (German Language)